EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

Screening outcome of HPV-vaccinated women: Data from the Danish Trial23 cohort study

Mette Hartmann Nonboe iD, George Maria Napolitano, Caroline Kann, Berit Andersen iD, Mary Holten Bennetsen, Sanne Christiansen, Anna Poulsgaard Frandsen, Carsten Rygaard, Rouzbeh Salmani, Jeppe Bennekou Schroll, Elsebeth Lynge

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0306044 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift PLOS ONE, 2024. Verfasst von Mette Hartmann Nonboe und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Health Research, Zealand University Hospital, Nykøbing Falster, Nykøbing Falster, Denmark. Hauptthemen laut MEDLINE: Papillomavirus Vaccines, Uterine Cervical Neoplasms, Papillomavirus Infections, Early Detection of Cancer. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk Fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Danish women—who were HPV-vaccinated as girls—are now reaching an age where they are invited to cervical cancer screening. Because of their expected lower cervical cancer risk, we must reassess our screening strategies. We analyzed Danish HPV-vaccinated women’s outcomes after the first screening test at age 23. Methods and findings Our study was embedded in Danish routine cytology-based screening. We conducted an observational study and included women born in 1994, offered the 4-valent HPV vaccine at age 14, and subsequently invited to screening at age 23. Cervical cytology was used for diagnostics and clinical management. Residual material was HPV tested with Cobas® 4800/6800. The most severe histology diagnosis within 795 days of screening was found through linkage with the Danish National Pathology Register. We calculated the number of women undergoing follow-up (repeated testing and/or colposcopy) per detected cervical intraepithelial neoplasia (CIN2+). A total of 6021 women were screened; 92% were HPV-vaccinated; 12% had abnormal cytology; 35% were high-risk HPV-positive, including 0.9% HPV16/18 positive, and 20% had follow-up. In women that were cytology-abnormal and HPV-positive (Cyt+/HPV+), 610 (98.5%) had been followed up, and 138 CIN2+ cases were diagnosed, resulting in 4.4 (95% CI 3.9–5.2) women undergoing follow-up per detected CIN2+. In contrast to recommendations, 182 (12.2%) cytology-normal and HPV-positive (Cyt-/HPV+) women were followed up within 795 days, and 8 CIN2+ cases were found, resulting in 22.8 (95% CI 13.3–59.3) women undergoing follow-up per detected CIN2+.

Conclusion

Overall, HPV prevalence was high in HPV-vaccinated women, but HPV16/18 had largely disappeared. In the large group of cytology-normal and HPV-positive women, 23 had been followed up per detected CIN2+ case. Our data indicated that primary HPV screening of young HPV-vaccinated women would require very effective triage methods to avoid an excessive follow-up burden.

Trial registration

Trial registration number: NCT0304955 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus VaccinesUterine Cervical NeoplasmsPapillomavirus InfectionsEarly Detection of CancerHumansFemaleDenmarkYoung AdultCohort StudiesUterine Cervical DysplasiaAdultAdolescentVaccinationHuman papillomavirus 18Mass Screening

Substanzen

Papillomavirus Vaccines

Autor:innen und Institutionen

  • Centre for Health Research, Zealand University Hospital, Nykøbing Falster, Nykøbing Falster, Denmark.
  • Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
  • Department of Gynaecology, Rigshospitalet, Copenhagen, Denmark.
  • University Research Clinic for Cancer Screening, Department of Public Health Programmes, Randers Regional Hospital, Randers, Denmark.
  • Department of Pathology, Randers Regional Hospital, Randers, Denmark.
  • Department of Pathology, Sydvestjysk Hospital, Esbjerg, Denmark.

ORCID-Profile: Mette Hartmann Nonboe, Berit Andersen

Förderung

  • Novo Nordisk Fonden

Zitieren

APA

Nonboe, M. H., Napolitano, G. M., Kann, C., Andersen, B., Bennetsen, M. H., Christiansen, S., Frandsen, A. P., Rygaard, C., Salmani, R., Schroll, J. B., & Lynge, E. (2024). Screening outcome of HPV-vaccinated women: Data from the Danish Trial23 cohort study. PLOS ONE. https://doi.org/10.1371/journal.pone.0306044

Vancouver

Nonboe MH, Napolitano GM, Kann C, Andersen B, Bennetsen MH, Christiansen S, et al. Screening outcome of HPV-vaccinated women: Data from the Danish Trial23 cohort study. PLOS ONE. 2024. doi:10.1371/journal.pone.0306044

BibTeX
@article{Nonboe2024,
  author = {Nonboe, Mette Hartmann and Napolitano, George Maria and Kann, Caroline and Andersen, Berit and Bennetsen, Mary Holten and Christiansen, Sanne and Frandsen, Anna Poulsgaard and Rygaard, Carsten and Salmani, Rouzbeh and Schroll, Jeppe Bennekou and Lynge, Elsebeth},
  title = {Screening outcome of HPV-vaccinated women: Data from the Danish Trial23 cohort study},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0306044}
}
Kostenlos starten →